Tolerability of Levodropropizine and Dropropizine in Children with Non-productive Cough
The study was performed in 25 Italian paediatric departments. The patients included were aged between 2 and 14 years, had non-productive coughs for which antitussive treatment was clinically indicated, irrespective of the underlying aetiology.
Of the 286 patients who were initially recruited, 19 were excluded before initiation of treatment because they did not meet the minimum requirement of cough frequency during the baseline assessment. Of the remaining 267 patients, 134 were randomly allocated to levodropropizine and 133 to dropropizine.
Daytime somnolence was twice as frequent among patients receiving dropropizine as among those receiving the S(-)enantiomer, but the difference between the two groups was not statistically significant. None of the patients reporting somnolence was taking any drug known to possess sedative effects.
Somnolence was generally mild, except in three dropropizine-treated patients in whom the adverse event was rated as severe, in one case leading to treatment interruption.
Seven patients (four in the levodropropizine group and three in the dropropizine group) complained of vomiting and/or abdominal pain and diarrhea during the study. Although a causal relationship with drug intake could not be ascertained, these events led to premature discontinuation of treatment in two patients in each of the two groups.
Heart rate and blood-pressure showed no clinically significant changes during the study. Mean values of haematology and blood chemistry tests did not evidence any significant change, except for those which could be ascribed to improvement of the underlying pathology.
In conclusion, the relative risk of developing daytime somnolence with levodropropizine appears to be about half that with dropropizine. Two patients dropped out because of severe somnolence in the dropropizine group, none in the levodropropizine group.
No opioid-like adverse events were reported and the drop-outs due to diarrhea and vomiting are of doubtful relationship to the study drugs because of concomitant treatments. Levodropropizine can be considered a valid safer alternative to opioid and centrally acting non-opioid antitussives, as well as to dropropizine, in children.
Postado por Leandro Roque
Os artigos mais populares
A Anvisa publicou, nesta quarta-feira (2/10), um alerta para o risco de defeitos de fechamento orofacial, principalmente casos de fenda p...
O escitalopram corresponde a um dos enantiômeros do citalopram, o S-citalopram (daí o próprio nome escitalopram). A mistura racêmica, ou...
Quem sofre de azia, gastrite ou refluxo provavelmente acostumou-se ao tratamento com medicamentos que são identificados como inibidores ...
A Boehringer Ingelheim do Brasil disponibilizou comunicado em seu site informando sobre a reativação de fabricação do medicamento Atens...
Quem faz uso de benzodiazepínicos antes de dormir pode experimentar uma espécie de ressaca no dia seguinte, sendo a tontura um sintoma ...
A data de validade de um medicamento pode sofrer diminuição quando a sua embalagem primária é violada. Para maior compreensão, vejamos o ...
A Takeda, fabricante do Ad-Til®, informou por meio de nota de esclarecimento no último dia 22 em seu site, que o fornecimento do produto...